histor
fast
result
clinic
microbiolog
laboratori
one
report
within
hour
specimen
receipt
recent
radic
movement
clinic
microbiolog
laboratori
provid
expediti
result
one
noteworthi
develop
introduct
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditof
ms
success
replac
tradit
biochem
identif
method
mani
institut
identificationfocus
approach
multiplex
pcr
microarraybas
technolog
technolog
advanc
focus
primarili
rapid
identif
microorgan
directli
clinic
specimen
includ
syndrom
panel
clear
food
drug
administr
vitro
diagnost
detect
varieti
organ
within
hour
rapid
identif
test
remark
significantli
shorten
time
identif
case
antimicrobi
optim
despit
advanc
identif
technolog
develop
faster
antimicrobi
suscept
test
ast
remain
stagnant
limit
potenti
impact
earli
pathogen
identif
effort
provid
antimicrobi
suscept
result
time
manner
evid
bloodstream
infect
syndrom
panel
may
detect
resist
marker
express
specif
gramposit
gramneg
organ
nonetheless
full
antimicrobi
suscept
profil
test
requir
mani
instanc
allow
target
therapi
articl
describ
approach
perform
ast
clinic
specimensisol
discuss
benefit
limit
genotyp
phenotyp
test
highlight
current
emerg
rapid
suscept
approach
neg
econom
outcom
across
varieti
scenario
includ
extendedspectrum
betalactamas
esbl
gramneg
bacteremia
urinari
tract
infect
methicillin
suscept
staphylococcu
aureu
mssa
bacteremia
pneumonia
sepsi
choos
empir
antimicrobi
regimen
clinician
must
weigh
risk
poor
patient
outcom
potenti
undertr
drugresist
pathogen
societ
import
antimicrobi
stewardship
complic
patientspecif
factor
includ
medic
allergi
renal
hepat
diseas
drug
interact
tabl
formulari
restrict
add
anoth
layer
intricaci
situat
difficult
choos
best
empir
agent
clinician
depend
result
microbiolog
laboratori
select
appropri
target
therapi
tradit
depend
cultur
suscept
result
although
paradigm
may
shift
mic
smallest
amount
drug
requir
inhibit
visibl
growth
microorgan
clinician
may
alway
appreci
mic
necessarili
reflect
efficaci
rather
simpli
laboratori
valu
reflect
relationship
drug
concentr
organ
kill
determin
whether
given
medic
use
particular
microb
infect
type
requir
knowledg
medic
pharmacokinet
pk
pharmacodynam
pd
paramet
pk
describ
interact
drug
host
absorpt
distribut
elimin
pd
detail
effect
drug
organ
combin
pkpd
paramet
along
mic
sever
factor
clinic
outcom
data
mic
isol
known
mechan
resist
lead
creation
clinic
breakpoint
guid
clinic
laboratori
report
strategi
suscept
drugbug
combin
report
suscept
indic
organ
adequ
respons
therapi
use
normal
recommend
dose
resist
indic
goal
achiev
sometim
intermedi
result
report
gener
indic
mic
zone
diamet
may
difficult
overcom
suscept
isol
clinic
efficaci
might
still
achiev
depend
dosag
site
infect
ad
complex
recent
categori
susceptibledos
depend
use
evid
aggress
dose
regimen
use
treat
infect
mic
suscept
resist
differ
intermedi
occasion
report
nonsuscept
may
seen
case
breakpoint
suscept
exist
resist
exceedingli
rare
nonsuscept
mean
isol
resist
mechan
instead
indic
evid
support
definit
suscept
final
drug
ie
colistin
epidemiolog
cutoff
valu
ecv
defin
upper
limit
suscept
wildtyp
popul
isol
import
emphas
ecv
clinic
breakpoint
provid
inform
purpos
tradit
phenotyp
suscept
test
perform
disk
diffus
broth
microdilut
agar
dilut
disk
diffus
depend
upon
abil
antibiot
molecul
diffus
disk
agar
form
circular
zone
zone
diamet
measur
hour
incub
compar
standard
chart
allow
qualit
suscept
interpret
addit
disk
diffus
clinic
laboratori
standard
institut
clsi
recogn
two
refer
standard
ast
method
broth
microdilut
agar
dilut
two
method
offer
mic
result
alongsid
clinic
breakpoint
interpret
contrast
limit
disk
diffus
method
absenc
mic
result
breakpoint
interpret
report
clinician
agar
dilut
requir
prepar
individu
agar
plate
premix
known
antibiot
concentr
allow
mic
assess
organ
dissolv
solut
inocul
plate
plate
lowest
drug
concentr
growth
determin
repres
mic
similarli
cumbersom
prepar
refer
broth
microdilut
rare
offer
outsid
refer
research
laboratori
therefor
mic
gener
obtain
via
autom
system
microscan
walkaway
bd
phoenix
vitek
sensititr
ari
system
strength
limit
unifi
low
requir
handson
time
use
intrins
interpret
rule
built
softwar
abil
provid
quantit
mic
valu
albeit
doubl
concentr
eg
etc
addit
gradient
diffus
ie
etest
liofilchem
combin
tabl
clinician
consider
choos
empir
antibiot
patient
expos
antibiot
recent
patient
resid
longterm
care
facil
multidrugresistantorgan
risk
factor
patient
prior
cultur
data
show
antimicrobi
resist
patient
take
medic
oral
intraven
antibiot
need
patient
stabl
venou
access
patient
renal
function
medic
patient
receiv
might
interact
would
typic
use
therapi
infect
antibiot
penetr
locat
antibiot
institut
outpati
insur
formulari
methodolog
disc
diffus
quantit
mic
result
method
util
antibioticimpregn
strip
decreas
gradient
shape
zone
inhibit
ellipt
mic
point
tip
ellips
touch
strip
standard
phenotyp
test
result
interpret
neither
easi
straightforward
best
report
result
provid
optim
inform
clinician
ongo
challeng
clsi
agenc
exampl
clinician
confus
surprisingli
common
question
choos
antibiot
lowest
mic
lead
teach
moment
drugbug
relationship
pkpd
aspect
consid
exampl
difficulti
understand
suscept
pattern
methicillinsuscept
staphylococci
eg
request
cefazolin
result
request
tetracyclin
suscept
result
enterococci
site
urin
despit
limit
phenotyp
test
avail
bacteria
regardless
locat
infect
appropri
report
mind
microbiolog
laboratori
provid
suscept
result
escherichia
coli
cerebr
spinal
fluid
blood
urin
bone
reason
reliabl
phenotyp
test
also
allow
nuanc
interpret
exampl
carbapenemaseproduc
klebsiella
isol
detect
enzymat
mutat
may
mic
decis
use
meropenem
part
treatment
regimen
may
part
determin
mic
knowledg
mic
could
repres
simpli
detect
carbapenemas
gene
phenotyp
test
gold
standard
method
guid
antimicrobi
treatment
decis
molecular
assay
may
chang
inher
flexibl
phenotyp
test
make
power
tool
treatment
infect
along
decad
experi
base
therapeut
decis
phenotyp
result
well
cost
eas
ensur
phenotyp
test
still
part
clinic
microbiolog
laboratori
practic
least
near
futur
genotyp
suscept
test
detect
resist
gene
express
specif
organ
molecular
method
exampl
clinic
laboratori
screen
methicillinresist
staphylococcu
aureu
mrsa
colon
detect
meca
gene
combin
bacteri
target
coupl
resist
determin
valuabl
compon
commerci
avail
blood
cultur
panel
tabl
summar
current
fdaclear
panel
well
panel
undergo
clinic
trial
incorpor
genotyp
resist
detect
alongsid
pathogen
identif
two
primari
gramposit
resist
target
meca
detect
mrsa
vana
vanb
detect
vancomycinresist
enterococci
vre
resist
gene
specif
gramneg
organ
includ
ctxm
detect
esbl
rang
carbapenemaseproduc
gene
ie
bla
kpc
bla
ndm
bla
vim
rapid
detect
presenc
absenc
resist
gene
may
allow
improv
antimicrobi
therapi
independ
phenotyp
suscept
result
evid
case
infect
gramposit
bacteria
tabl
rule
methicillin
resist
aureu
bloodstream
infect
base
absenc
meca
express
allow
deescal
vancomycin
antistaphylococc
betalactam
agent
cefazolin
oxacillin
nafcillin
within
hour
rather
day
hand
earli
detect
vancomycin
resist
enterococcu
speci
detect
vana
vanb
ensur
escal
antimicrobi
therapi
patient
vancomycin
empir
therapi
sever
studi
support
posit
patient
outcom
rapid
genotyp
suscept
result
avail
within
hour
blood
cultur
posit
one
decreas
treatment
coagulaseneg
staphylococc
bacteremia
rapid
chang
appropri
therapi
vre
bacteremia
anoth
group
demonstr
faster
initi
appropri
esbl
bacteremia
therapi
reduct
intens
care
unit
length
stay
although
wide
avail
clinic
use
genotyp
screen
gyra
gene
neisseria
gonorrhoea
proven
highli
predict
ciprofloxacin
resist
addit
screen
extendedspectrum
cephalosporin
target
pena
mosaic
xxxiv
yield
high
sensit
specif
respect
particularli
relev
major
gonococc
infect
diagnos
molecular
method
recoveri
organ
ast
uncommon
addit
benefit
genotyp
test
depend
live
cell
detect
may
benefici
patient
prior
exposur
antimicrobi
agent
current
rather
replac
phenotyp
suscept
test
genotyp
test
supplement
import
concept
emphas
mani
incid
absenc
resist
gene
necessarili
predict
suscept
particular
drug
evid
gramneg
resist
marker
includ
bloodstream
infect
panel
tabl
instanc
molecular
detect
e
coli
posit
blood
cultur
absenc
bla
ctxm
bla
kpc
equal
suscept
cephalosporin
carbapenem
mani
resist
mechan
consid
porin
loss
efflux
pump
well
numer
addit
esbl
carbapenemas
gene
may
produc
e
coli
isol
line
issu
modest
number
resist
gene
includ
panel
hinder
antimicrobi
stewardship
even
absenc
target
resist
gene
mention
limit
relev
gramneg
organ
also
noteworthi
gramposit
organ
instanc
mrsa
isol
harbor
mecc
gene
diverg
meca
gene
would
misidentifi
mssa
verigen
gramposit
blood
cultur
panel
filmarray
blood
cultur
identif
bcid
panel
unfortun
addit
phenotyp
suscept
test
use
commerci
system
may
also
interpret
isol
fals
suscept
attempt
avoid
potenti
fals
neg
caus
meccharbor
mrsa
xpert
mrsa
gen
cepheid
sunnyval
ca
recent
fda
clear
molecular
test
screen
mrsa
use
meca
mecc
nonetheless
imper
commerci
compani
continu
improv
molecular
panel
incorpor
new
relev
resist
target
maxim
util
test
respect
antimicrobi
stewardship
patient
manag
final
detect
gramneg
resist
gene
necessarili
predict
therapeut
failur
clsi
requir
routin
screen
esbl
carbapenemas
product
recommend
test
epidemiolog
infect
control
purpos
predict
resist
sole
base
detect
specif
resist
gene
may
result
overcal
resist
unnecessari
util
broader
antimicrobi
agent
mention
technolog
advanc
primarili
offer
genotyp
marker
suscept
test
solut
number
fdaclear
assay
detect
aureu
well
meca
gene
directli
posit
blood
cultur
tabl
verigen
blood
cultur
panel
luminex
corpor
austin
tx
filmarray
bcid
panel
biofir
diagnost
salt
lake
citi
ut
offer
comprehens
panel
target
gramposit
gramneg
organ
well
respect
resist
marker
filmarray
bcid
panel
also
includ
target
five
candida
speci
numer
studi
perform
panel
report
high
agreement
identif
resist
gene
compar
convent
identif
ast
method
meca
vana
vanb
gene
high
predict
valu
aureu
suscept
oxacillin
andor
cefoxitin
enterococc
suscept
vancomycin
respect
discrep
molecular
phenotyp
result
may
seen
clsi
provid
guid
assist
laboratorian
investig
situat
includ
recommend
report
discord
molecular
phenotyp
assay
aureu
oxacillin
enterococcu
spp
vancomycin
enterobacteriacea
extendedspectrum
betalactam
take
home
messag
follow
discrep
remain
unresolv
tabl
case
exampl
demonstr
role
gramposit
resist
marker
optim
antimicrobi
therapi
male
histori
intraven
drug
use
admit
sign
symptom
infect
endocard
fever
new
right
sternal
systol
heart
murmur
acut
renal
failur
leukocytosi
met
hospit
sepsi
protocol
criteria
receiv
empir
vancomycin
plu
piperacillintazobactam
workup
posit
blood
cultur
molecular
identif
plu
genotyp
ast
panel
reveal
mssa
result
report
within
hour
time
blood
cultur
posit
identif
mssa
blood
cultur
confirm
case
endocard
caus
gramposit
organ
piperacillintazobactam
may
discontinu
absenc
meca
gene
molecular
method
indic
pathogen
could
treat
betalactam
agent
still
small
nonzero
possibl
polymicrobi
bacteremia
particularli
sourc
contamin
needl
addit
clindamycin
rifampin
patient
would
still
requir
phenotyp
suscept
result
clinician
agre
narrow
therapi
nafcillin
tabl
case
exampl
demonstr
role
gramneg
resist
marker
optim
antimicrobi
therapi
femal
admit
chemotherapyinduc
neutropen
fever
empir
start
meropenem
vancomycin
accord
hospit
protocol
set
blood
cultur
collect
workup
posit
blood
cultur
molecular
identif
plu
genotyp
ast
panel
reveal
klebsiella
pneumonia
kpc
gene
detect
result
report
within
hour
time
blood
cultur
posit
identif
k
pneumonia
blood
cultur
confirm
case
gramneg
bloodstream
infect
vancomycin
might
discontinu
caveat
would
patient
high
risk
polymicrobi
infect
might
justifi
maintain
gramposit
coverag
absenc
kpc
gene
mean
absenc
carbapenemas
gene
express
organ
deescal
therapi
might
warrant
absenc
kpc
mean
meropenem
appropri
coverag
might
resist
mechan
involv
might
result
resist
carbapenem
way
determin
base
molecular
result
clinician
declin
narrow
therapi
lack
data
show
organ
suscept
altern
agent
cefepim
addit
test
organ
report
resist
respect
antimicrobi
agent
genotyp
suscept
also
applic
clinic
sourc
excel
exampl
xpert
platform
cepheid
coupl
pathogen
identif
resist
detect
sputum
detect
mycobacterium
tuberculosi
complex
rpob
gene
predict
resist
rifampin
multicent
studi
patient
suspect
pulmonari
tuberculosi
report
correct
predict
rifampinresist
tuberculosi
complex
isol
rifampinsuscept
tuberculosi
complex
isol
recent
studi
report
high
predict
valu
rifampinresist
bacteria
mean
agreement
drug
regimen
genotyp
phenotyp
suscept
reiter
need
complement
genotyp
suscept
test
phenotyp
test
avoid
ineffect
treatment
regimen
lone
fdaclear
panel
offer
expedit
phenotyp
suscept
test
posit
blood
cultur
acceler
phenotest
bc
acceler
diagnost
tucson
az
panel
offer
detect
gramposit
gramneg
bacteria
well
two
yeast
target
fluoresc
situ
hybrid
fish
de
gener
mic
valu
use
morphokinet
cellular
analysi
individu
immobil
bacteri
cell
everi
minut
presenc
absenc
antimicrobi
agent
drugspecif
test
singl
concentr
antibiot
use
provid
mic
categor
interpret
suscept
intermedi
resist
approxim
hour
repres
innov
first
step
quest
rapid
phenotyp
suscept
test
clinic
trial
conduct
across
us
institut
prospect
clinic
sampl
seed
sampl
essenti
agreement
ea
categor
agreement
ca
rang
major
error
major
error
vme
similarli
singlecent
us
studi
posit
blood
cultur
report
ea
ca
vme
me
investig
report
substanti
decreas
time
suscept
result
almost
hour
compar
standardofcar
test
reduct
handson
time
minut
test
elimin
need
subcultur
posit
blood
cultur
ensur
detect
organ
includ
panel
howev
major
case
phenotest
bc
function
standalon
test
sens
subsequ
ast
cultur
requir
view
limit
option
avail
rapid
phenotyp
ast
clinic
laboratori
taken
upon
provid
solut
clinician
doern
colleagu
report
promis
disk
diffus
ast
result
blood
cultur
use
quick
dirti
approach
drop
blood
cultur
broth
muellerhinton
agar
numer
studi
also
report
high
agreement
compar
convent
ast
use
approach
gener
bacteri
cell
pellet
test
commerci
autom
ast
system
unfortun
approach
widespread
clinic
laboratori
reason
includ
limit
resourc
expertis
regulatori
concern
use
laboratorydevelop
test
low
sens
urgenc
due
percept
patient
appropri
empir
therapi
therefor
order
ensur
widespread
dissemin
clinic
laboratori
develop
directfromspecimen
ast
system
reasonablelow
cost
need
prioriti
instanc
recent
proofofconcept
studi
clsi
ast
subcommitte
ad
hoc
work
group
direct
ast
blood
cultur
conduct
goal
develop
standard
direct
blood
cultur
ast
perform
laboratori
preliminari
data
indic
ca
incub
develop
panel
genotyp
resist
detect
ongo
eplex
bcid
panel
genmark
diagnost
carlsbad
ca
current
undergo
clinic
trial
offer
resist
marker
ident
verigen
blood
cultur
panel
except
mecc
tabl
filmarray
pneumonia
panel
next
test
offer
biofir
diagnost
offer
first
semiquantit
multiplex
panel
detect
bacteria
well
qualit
detect
virus
atyp
bacteria
resist
marker
includ
panel
line
eplex
assay
likewis
unyvero
platform
cureti
san
diego
ca
lower
respiratori
tract
applic
recent
fda
clear
consist
pathogen
target
resist
marker
addit
commerci
genotyp
ast
assay
come
pipelin
refer
review
dunn
et
al
certainli
enthusiasm
faster
phenotyp
ast
varieti
clinic
specimen
demonstr
influx
innov
strategi
sever
approach
explor
includ
digit
realtim
loopmedi
isotherm
amplif
dlamp
partner
microfluid
nanotechnolog
dlamp
assay
propos
phenotyp
ast
result
within
min
directli
clinic
urin
sampl
recent
proofofprincipl
studi
introduc
microscopybas
ast
platform
consist
solidphas
microwel
growth
surfac
allow
restrict
cell
microfluid
channel
propos
time
ast
approxim
hour
although
live
cultur
bacteria
requir
test
refer
review
li
et
al
excel
summari
emerg
technolog
phenotyp
ast
despit
mani
proofofconcept
system
develop
mariast
arcdia
finland
commerci
avail
none
avail
us
one
system
commerci
prospect
lifescaleast
system
lifescal
santa
barbara
ca
employ
ultrahigh
solut
mass
measur
determin
individu
microb
mass
initi
panel
offer
test
gramneg
bacilli
posit
blood
cultur
use
custom
sensititr
plate
allow
mic
determin
breakpoint
interpret
approxim
hour
sinc
identif
featur
drawback
system
reliant
adopt
rapid
identif
test
clinic
laboratori
maxim
util
test
anoth
upcom
assay
smarticl
roch
pleasanton
ca
use
recombin
bacteriophag
dna
probe
bind
specif
bacteri
target
deliv
customdesign
dna
molecul
caus
viabl
bacteria
express
luciferas
exampl
absenc
luciferas
express
sampl
mix
defin
concentr
antibiot
would
interpret
suscept
public
two
system
date
anoth
promis
system
uti
system
bacterioscan
st
loui
mo
system
util
forward
laser
lightscatt
technolog
rapidli
screen
urin
presenc
bacteria
limit
detect
cfuml
technolog
proven
perform
ast
directli
urin
sampl
promis
result
innov
approach
acceler
diagnost
develop
lower
respiratori
tract
panel
pheno
system
describ
offer
identif
phenotyp
ast
featur
continu
uniqu
among
fdaclear
system
includ
lower
respiratori
tract
panel
offer
biofir
diagnost
cureti
potenti
downsid
method
howev
increas
cost
compar
tradit
suscept
test
method
despit
enthusiasm
new
emerg
ast
technolog
regulatori
polici
pose
continu
challeng
clinic
laboratori
diagnost
manufactur
excel
review
humphri
hindler
highlight
challeng
encount
includ
frequent
modifi
clinic
breakpoint
new
antimicrobi
agent
avail
test
commerci
system
breakpoint
restrict
organ
includ
clinic
trial
author
offer
potenti
solut
problem
via
collabor
effort
among
multipl
entiti
includ
fda
cdc
diagnost
manufactur
pharmaceut
manufactur
challeng
practic
consider
cost
staff
train
health
care
cost
continu
close
scrutin
clinic
microbiolog
laboratori
health
care
system
need
consid
cost
assay
relat
clinic
outcom
mention
assay
add
addit
workflow
complex
rather
replac
tradit
microbiolog
outcom
data
also
mix
posit
result
rapid
blood
cultur
molecular
ast
detect
describ
data
support
deescal
much
less
robust
reflect
limit
kit
well
lack
physician
confid
understand
molecular
result
lastli
paramount
import
clinic
laboratori
assess
perform
new
technolog
prior
implement
ensur
discrep
antimicrobi
suscept
compar
refer
method
minimum
exampl
drugbug
combin
prone
vme
laboratori
consid
withhold
result
perform
secondari
ast
prior
report
rapid
detect
organ
name
suscept
pattern
potenti
profoundli
alter
treatment
plan
patient
outcom
novel
method
access
clinic
microbiolog
laboratori
design
identifi
resist
marker
quickli
determin
suscept
profil
mani
challeng
remain
includ
need
valid
assay
ensur
result
understand
clinician
cost
exceed
benefit
excit
time
work
field
clinic
microbiolog
infecti
diseas
